Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27678492 | 0.92 | MAPT (0.54) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL6651894 | 0.80 | KDM4E (0.71) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL4899071 | 0.78 | MAPT (0.54) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL4908281 | 0.75 | MAPT (0.57) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL5654106 | 0.75 | SMN1; SMN2 (0.49) | MAPTL3MBTL1KMT2AALDH1A1TLR8 | |
| SCHEMBL4908674 | 0.73 | MAPT (0.52) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| Butyl Chloride SCHEMBL27485209 | 0.73 | KDM4E (0.56) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL4910266 | 0.72 | MAPT (0.48) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL4912548 | 0.72 | MAPT (0.48) | MAPTL3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL11669834 | 0.71 | LMNA (0.57) | MAPTL3MBTL1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | MAPT 3095/4885L3MBTL1 2184/4885LMNA 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.